Details

Autor(en) / Beteiligte

• Montravers, Françoise
• Kerrou, Khaldoun
• Nataf, Valérie
• Huchet, Virginie
• Lotz, Jean-Pierre
• Ruszniewski, Philippe
• Rougier, Philippe
• Duron, Françoise
• Bouchard, Philippe
• Grangé, Jean-Didier
• Houry, Sydney
• Talbot, Jean-Noël

Titel

Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors

Ist Teil von

• The journal of clinical endocrinology and metabolism, 2009-04, Vol.94 (4), p.1295-1301

Ort / Verlag

Bethesda, MD: Endocrine Society

Erscheinungsjahr

2009

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Context and Objectives: Fluorodihydroxyphenylalanine-(18F) (FDOPA) positron emission tomography (PET) is a recent imaging modality used to localize endocrine tumors. This study was conducted to evaluate the impact of FDOPA-PET on the management of patients referred for carcinoid or noncarcinoid digestive tumors and the clinical relevance of the treatment decisions based on this examination. Methods and Patients: Between March 2002 and December 2006, 101 FDOPA-PET examinations were performed in 78 adult patients for follow-up of histologically documented carcinoid tumor of the ileum (23 patients) or noncarcinoid digestive tumor (26 patients) or to screen for occult digestive endocrine tumors (29 patients). More than one FDOPA-PET examination was performed in 12 patients. The impact of FDOPA PET was evaluated on a per-patient basis by means of a questionnaire completed by the referring physician, and the relevance of the treatment decision was assessed on the basis of follow-up data. Results: The survey response rate was 91% (71 of 78). The overall impact rate of FDOPA-PET on patient management was 25% (18 of 71). The greatest impact was observed for carcinoid tumors (50%: 11 of 22) and was clinically relevant in every case, followed by occult endocrine tumors (16%: four of 25), and was clinically relevant in three of the four cases, and noncarcinoid tumors (13%: 3 of 22), clinically relevant in only one case. Conclusion: FDOPA-PET appears to be a major tool for the management of carcinoid tumors with excellent diagnostic performances and induced relevant changes in patient management. FDOPA-PET was less sensitive and less useful for the management of noncarcinoid tumors. F-DOPA-PET appears to be a valuable tool for management of gastrointestinal carcinoid tumors with excellent diagnostic performance capable of bringing about changes in patient management.